These drugs have been linked to improvements in subjective symptoms of ROSAH, while tocilizumab (anti-IL-6) showed early promising data with reduced ocular inflammation in patients unresponsive to TNF and IL-1 inhibition3. Here, IL1B is linked to retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache syndrome.